


Erectile Dysfunction Devices Market Anticipated to Grow to USD 10.5 Billion at 6.22% CAGR by 2035

The global market for erectile dysfunction devices is being driven by various key factors. Increasing awareness about men's health issues

US, NY, UNITED STATES, September 3, 2025 /EINPresswire.com/ -- The [Erectile Dysfunction Devices Market](#)—a critical and evolving segment within men's health technologies—is on track to expand significantly, growing from an estimated USD 5.09 billion in 2023 to

USD 5.41 billion in 2024, and projected to reach USD 10.5 billion by 2035, according to a recent release from (MRFR) . This impressive expansion corresponds to a compound annual growth rate (CAGR) of approximately 6.22 percent between 2025 and 2035 .



Industry Size & Market Share

As of 2024, the erectile dysfunction devices industry is valued at USD 5.41 billion, reflecting growing global demand among men's health providers, hospitals, and consumers . Within this figure, North America leads, with an estimated market size of USD 2.16 billion, followed by Europe at USD 1.78 billion, Asia-Pacific at USD 1.2 billion, and smaller but growing shares in South America (USD 0.15 billion) and MEA (USD 0.12 billion) .

Request To Free Sample of This Strategic Report:

https://www.marketresearchfuture.com/sample_request/43302

Segment Growth & Market Scope

The market's segmentation by device type reveals dynamic shifts and growth opportunities:

Vacuum Erection Devices (VEDs) held substantial interest in 2024, valued at USD 1.26 billion, and expected to reach USD 2.51 billion by 2035 .

Penile Implants stood out in 2024 at USD 2.15 billion, representing the largest slice of market

share .

Injection Therapy Devices reached USD 1.25 billion in 2024 .

Topical Drug Delivery Devices, while the smallest, still held USD 0.75 billion in 2024 .

These figures underscore the market scope across multiple therapeutic modalities—from non-invasive to surgical solutions—providing variety for healthcare providers and vendors alike.

End-User, Patient & Distribution Channel Insights

In terms of end users, MRFR identifies Home Use, Medical Institutions, and Pharmacies as key channels, each playing pivotal roles in accessibility, patient comfort, and professional service delivery .

The patient population is categorized into Primary Erectile Dysfunction (often lifestyle or psychological) and Secondary Erectile Dysfunction (linked to comorbidities like diabetes or cardiovascular disease), both fueling demand .

Distribution pathways are equally diverse: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies support consumers' preferences for privacy, immediacy, and clinical oversight .

You Can Purchase Complete Report:

https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=43302

Emerging Trends & Recent Developments

The market is being propelled by technological advancements—including more effective, user-friendly designs in vacuum devices, implants, and injection systems—as well as growing patient and clinician awareness of ED as a legitimate health priority rather than a taboo subject .

The aging global population, rising prevalence of comorbid conditions, and expanding telehealth capabilities further accelerate market expansion .

Notable recent developments include:

Q2 2024: Boston Scientific obtained FDA approval for the AMS 700™ Inflatable Penile Prosthesis featuring a new hydrophilic coating, aimed at reducing infection and enhancing surgical outcomes .

Q1 2024: Coloplast launched the Titan Touch™ Penile Implant in the U.S., enhancing ease of use for clinicians and patients .

Q2 2024: Zephyr Surgical Implants received the CE Mark for the ZSI 475 hydraulic penile prosthesis for the EU marketplace .

Late 2024–Early 2025: Boston Scientific expanded its manufacturing facility in Minnesota to meet growing global demand .

Q2 2025: UroMems closed a USD 47 million Series C funding, advancing smart implantable devices for ED .

Q1 2025: UroMems achieved a milestone with its first-in-human implantation of the UroActive™ Smart Penile Prosthesis .

Additionally, Coloplast signed a distribution agreement with Medtronic for expansion in the Asia-Pacific region, and launched a telehealth partnership with Hims & Hers to broaden access in the U.S. .

Top Companies & Competitive Landscape

The competitive arena features a balanced mix of traditional device manufacturers, pharmaceutical players, and emerging innovators, including:

VIVUS, Suneva Medical, Aytu BioScience, CaverStem, Sexual Health Innovations, Neos Therapeutics, Pfizer, Coloplast, Endo Pharmaceuticals, Ereca, Boston Scientific, Bayer, Astellas Pharma, Medtronic, and Uromed, Inc. .

These players are driving the market share race via strategic investments: tech innovation, geographic expansion, digital channels, and smart-prosthetic development.

Opportunities & Future Outlook

For manufacturers, this landscape suggests opportunities in smart device R&D, implant enhancements, and minimally invasive solutions targeting aging and co-morbid populations. Procurement heads and hospital administrators can leverage telehealth and hybrid distribution models to improve reach and cost-effectiveness.

Distributors may rapidly gain ground by serving under-penetrated regions such as South America and MEA, while also deepening presence in APAC's expanding healthcare markets. Investors stand to benefit from the favorable CAGR of 6.22 percent, the market's projected doubling to USD 10.5 billion by 2035, and the sector's technological transformation toward personalized, smart, and patient-centric solutions.

About the Report

The "Erectile Dysfunction Devices Market Size, Growth Report 2032" from MRFR is anchored in rigorous primary and secondary research, analyst validation, and proprietary market databases. It offers comprehensive forecasting, segmentation, competitive mapping, and insight into revenue trends, growth factors, and innovation trajectories .

Market Research Future

Market Research Future

+1 855-661-4441

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/845570576>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.